Bartlett & Co. LLC cut its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,730 shares of the medical equipment provider’s stock after selling 120 shares during the period. Bartlett & Co. LLC’s holdings in Zimmer Biomet Holdings were worth $607,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also bought and sold shares of the company. MARSHALL WACE ASIA Ltd acquired a new position in Zimmer Biomet Holdings during the first quarter valued at $38,621,000. Cibc World Markets Corp boosted its position in Zimmer Biomet Holdings by 52.9% in the first quarter. Cibc World Markets Corp now owns 21,007 shares of the medical equipment provider’s stock valued at $2,565,000 after buying an additional 7,269 shares in the last quarter. Caxton Associates LP acquired a new position in Zimmer Biomet Holdings during the first quarter valued at $403,000. Thrivent Financial for Lutherans boosted its position in Zimmer Biomet Holdings by 6.7% in the fourth quarter. Thrivent Financial for Lutherans now owns 7,144 shares of the medical equipment provider’s stock valued at $737,000 after buying an additional 450 shares in the last quarter. Finally, Auxier Asset Management boosted its position in Zimmer Biomet Holdings by 3.3% in the fourth quarter. Auxier Asset Management now owns 86,514 shares of the medical equipment provider’s stock valued at $8,928,000 after buying an additional 2,750 shares in the last quarter. Hedge funds and other institutional investors own 83.62% of the company’s stock.
Shares of Zimmer Biomet Holdings, Inc. (NYSE ZBH) traded up 1.43% during trading on Friday, hitting $111.70. The stock had a trading volume of 1,497,171 shares. Zimmer Biomet Holdings, Inc. has a 12-month low of $95.63 and a 12-month high of $133.49. The firm has a market cap of $22.59 billion, a P/E ratio of 31.81 and a beta of 1.20. The firm has a 50 day moving average price of $124.93 and a 200 day moving average price of $121.26.
Zimmer Biomet Holdings (NYSE:ZBH) last posted its earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 EPS for the quarter, missing the Zacks’ consensus estimate of $2.10 by $0.02. Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. The business had revenue of $1.95 billion for the quarter, compared to analyst estimates of $1.95 billion. During the same quarter last year, the business earned $2.02 earnings per share. Zimmer Biomet Holdings’s revenue was up 1.1% on a year-over-year basis. On average, equities analysts expect that Zimmer Biomet Holdings, Inc. will post $8.24 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 22nd will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.86%. The ex-dividend date of this dividend is Thursday, September 21st. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is presently 27.59%.
ILLEGAL ACTIVITY NOTICE: “Bartlett & Co. LLC Has $607,000 Position in Zimmer Biomet Holdings, Inc. (ZBH)” was first posted by BNB Daily and is the sole property of of BNB Daily. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.baseball-news-blog.com/2017/08/13/zimmer-biomet-holdings-inc-zbh-position-reduced-by-bartlett-co-llc-updated-updated-updated.html.
Several research analysts have recently weighed in on ZBH shares. Goldman Sachs Group, Inc. (The) initiated coverage on Zimmer Biomet Holdings in a research note on Tuesday, May 16th. They issued a “sell” rating and a $92.00 price target for the company. Canaccord Genuity reaffirmed a “buy” rating on shares of Zimmer Biomet Holdings in a report on Friday, April 28th. Wells Fargo & Company lowered Zimmer Biomet Holdings from an “outperform” rating to a “market perform” rating in a report on Friday, April 28th. Zacks Investment Research lowered Zimmer Biomet Holdings from a “hold” rating to a “strong sell” rating in a report on Tuesday, August 8th. Finally, Morgan Stanley lifted their price objective on Zimmer Biomet Holdings from $137.00 to $150.00 and gave the stock an “overweight” rating in a report on Monday, July 17th. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $136.90.
In other news, VP Tony W. Collins sold 16,986 shares of the firm’s stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $121.74, for a total transaction of $2,067,875.64. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Sang Yi sold 17,731 shares of the firm’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $124.56, for a total value of $2,208,573.36. The disclosure for this sale can be found here. 1.07% of the stock is owned by company insiders.
About Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.